Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beigene Ltd ADR
(NQ:
BGNE
)
193.82
-1.81 (-0.93%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 13, 2024
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24...
Via
Benzinga
BeiGene Ltd. (NASDAQ: BGNE) is a Leading Gainer in 3/13 Morning Trading
March 13, 2024
Via
Investor Brand Network
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
March 13, 2024
From
BeiGene
Via
Business Wire
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
March 13, 2024
U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday.
Via
Benzinga
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
March 08, 2024
FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at...
Via
Benzinga
Exposures
Product Safety
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
March 07, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
March 06, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
February 29, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present at Upcoming Investor Conferences
February 28, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
February 27, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 26, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
February 26, 2024
From
BeiGene, Ltd.
Via
Business Wire
Hang Seng Index Set For Global Expansion With Prada, XPeng, And BeiGene On The Horizon
February 16, 2024
This development comes at a time when the city is grappling with a declining market.
Via
Benzinga
Get Rich Quick With These 3 Biotech Stocks to Buy Now
February 13, 2024
The new cycle is coming your way to boost millionaire-making securities. Check out these three biotech stocks to buy.
Via
InvestorPlace
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
February 06, 2024
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.
Via
InvestorPlace
JP Morgan's Bullish View On This Chinese Biotech, Says Pullback Creates Entry Point
February 06, 2024
BeiGene's JP Morgan coverage highlights upside in valuation post-pullback. Brukinsa's success and Tevimbra's potential add to the optimism. Overweight rating, $185 price target.
Via
Benzinga
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
January 23, 2024
From
BeiGene, Ltd.
Via
Business Wire
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
January 15, 2024
These five biotech companies could have a lot of room to run.
Via
The Motley Fool
As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks?
January 10, 2024
Exploring the economic implications of China's declining population on property markets and the potential rise of healthcare and tech investments.
Via
Benzinga
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
January 07, 2024
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech...
Via
Talk Markets
HBM Gets Health Boost From Drug Licensing Deals
December 22, 2023
Key Takeaways: Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech for an initial sum of $53 million and milestone payments of up to $1.05...
Via
Benzinga
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
December 22, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
November 29, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
November 28, 2023
From
BeiGene, Ltd.
Via
Business Wire
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem
November 25, 2023
Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem will receive an upfront...
Via
Talk Markets
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
November 21, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
November 17, 2023
From
BeiGene, Ltd.
Via
Business Wire
7 Biotech Stocks to Buy for Big-Time Gains
November 10, 2023
Biotech stocks can be big winners because they're at the forefront of scientific innovation and push the boundaries of medical research.
Via
InvestorPlace
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
November 09, 2023
From
BeiGene, Ltd.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.